Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
The return on equity (ROE) is N/A as of the fiscal period ended Wednesday, December 31, 2025.
Limited history available
ALMR Return on Equity (ROE) has fewer than three reported periods, so a trend chart would be misleading.
RETURN ON EQUITY (ROE)
N/A
RETURN ON EQUITY (ROE) AVG TTM
9.38%
RETURN ON EQUITY (ROE) AVG 3Y
N/A
RETURN ON EQUITY (ROE) AVG 5Y
N/A
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Alamar Biosciences, Inc.
Market Cap
$2.24B
Return on Equity (ROE)
N/A
TTM Avg
9.38%
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$2.28B
Return on Equity (ROE)
18.14%
TTM Avg
20.16%
3Y Avg
28.24%
5Y Avg
15.58%
Market Cap
$2.17B
Return on Equity (ROE)
-57.96%
TTM Avg
-57.45%
3Y Avg
-48.08%
5Y Avg
-40.68%
Market Cap
$2.17B
Return on Equity (ROE)
-37.82%
TTM Avg
-53.05%
3Y Avg
-23.57%
5Y Avg
8.38%
Market Cap
$2.30B
Return on Equity (ROE)
71.04%
TTM Avg
-161.38%
3Y Avg
-133.53%
5Y Avg
-111.86%
Market Cap
$2.13B
Return on Equity (ROE)
-43.55%
TTM Avg
-14.07%
3Y Avg
-80.41%
5Y Avg
-980.81%
Market Cap
$2.34B
Return on Equity (ROE)
15.63%
TTM Avg
16.66%
3Y Avg
16.66%
5Y Avg
13.72%
Market Cap
$2.35B
Return on Equity (ROE)
-84.78%
TTM Avg
-42.91%
3Y Avg
-54.25%
5Y Avg
-44.36%
Market Cap
$2.36B
Return on Equity (ROE)
41.39%
TTM Avg
43.71%
3Y Avg
5.79%
5Y Avg
-18.90%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Alamar Biosciences, Inc. (ALMR) | $2.24B | N/A | 9.38% | N/A | N/A |
| Harmony Biosciences Holdings, Inc. (HRMY)vs › | $2.28B | 18.14% | 20.16% | 28.24% | 15.58% |
| Pharvaris N.V. (PHVS)vs › | $2.17B | -57.96% | -57.45% | -48.08% | -40.68% |
| Maravai LifeSciences Holdings, Inc. (MRVI)vs › | $2.17B | -37.82% | -53.05% | -23.57% | 8.38% |
| Liquidia Corporation (LQDA)vs › | $2.30B | 71.04% | -161.38% | -133.53% | -111.86% |
| GeneDx Holdings Corp. (WGS)vs › | $2.13B | -43.55% | -14.07% | -80.41% | -980.81% |
| UFP Technologies, Inc. (UFPT)vs › | $2.34B | 15.63% | 16.66% | 16.66% | 13.72% |
| Nurix Therapeutics, Inc. (NRIX)vs › | $2.35B | -84.78% | -42.91% | -54.25% | -44.36% |
| ADMA Biologics, Inc. (ADMA)vs › | $2.36B | 41.39% | 43.71% | 5.79% | -18.90% |
| Addus HomeCare Corporation (ADUS)vs › | $2.11B | 9.17% | 8.21% | 8.13% | 7.80% |
ROE
N/A
ROA
-21.3%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2025-12-31 | 18.76% |
| 2024-12-31 | 0.00% |
